COMPOUNDCagrilintide
ALIASNN9838 / CagriSema component
CLASSLong-Acting Amylin Analog
DEVELOPERNovo Nordisk
TRIAL STATUSPhase 3 (CagriSema combination)
HALF-LIFE~7 days
FDA STATUSNot approved
BEST PRICE$5.60/mg (Amino Club + PEPTIDEX)
LAST VERIFIEDMay 2026
Cagrilintide
Last reviewed June 3, 2026
Also known as: NN9838, AM833
Quick Answer
Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk for the CagriSema combination trial — dual amylin + GLP-1 agonism for weight loss exceeding semaglutide alone. I source from Amino Club using code PEPTIDEX: $55.99 per 10mg vial after the 20% discount ($5.60/mg). Phase 3 CagriSema data expected 2026. Research compound only — not FDA-approved.
Where to Source
Ranked by $/mg1Amino Club Best $/mg
$55.99
$69.99Save $14.00
10mg vial
$7.00/mg
99%+ purityCOA · Apr 2026
Use code for 20% off:
Shop Amino Club Compare all 2 vendors →
Rankings independent · Research use only
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinc
Where to Buy Cagrilintide
COA-verified vendors · Use code PEPTIDEX for up to 20% off
* Prices for research peptide acquisition. Not therapeutic products.
| Vendor | Purity | List Price | With PEPTIDEX | Code | Shop |
|---|---|---|---|---|---|
Amino ClubEditor's Pick | 99%+ | $69.9910 mg | $55.99Save 20% | PEPTIDEX | * Research vendor — verify your regional regulations before purchase. Shop |
Bio Longevity LabsTriple-Tested | 99%+ | $170.005 mg | $144.50Save 15% | PEPTIDEX | * Research vendor — verify your regional regulations before purchase. Shop |
Amino ClubEditor's Pick
$69.99 · 10 mg$55.99−20%
Use code PEPTIDEX for 20% off at Amino Club.
* Research vendor — verify your regional regulations before purchase.
Shop at Amino ClubBio Longevity LabsTriple-Tested
$170.00 · 5 mg$144.50−15%
Use code PEPTIDEX for 15% off at Bio Longevity Labs.
* Research vendor — verify your regional regulations before purchase.
Shop at Bio Longevity Labs§ Mechanism of Action
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
§ Primary Benefits
- 1Weight loss
- 2appetite reduction
- 3glycemic control
§ Clinical Evidence
Cagrilintide Phase 2 trial for weight management
Lau et al. (Lancet): Phase 2 RCT showing cagrilintide 4.5mg weekly achieved 10.8% weight loss vs 3.0% placebo at 26 weeks, with acceptable safety profile.
StrongCagriSema (cagrilintide + semaglutide) Phase 2 results
Frias et al. (Lancet): CagriSema combination achieved 15.6% weight loss at 32 weeks in type 2 diabetes patients — superior to either agent alone.
StrongAmylin analogs in obesity management: mechanism review
Review of amylin's role in energy homeostasis and why dual amylin-calcitonin receptor agonists like cagrilintide represent a new weight loss mechanism distinct from GLP-1.
ModerateEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
A 2026 randomized controlled trial demonstrated that co-administering cagrilintide and semaglutide resulted in a significantly greater bodyweight reduction (-18.4%) compared to semaglutide alone (-11.9%) over 68 weeks in East Asian adults with overweight or obesity.
Very StrongObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Next-generation multi-receptor agonists and amylin analogs demonstrated weight reductions of up to 24% and improved metabolic outcomes beyond traditional GLP-1 therapies. A 2026 review investigated these emerging treatments, highlighting a shift toward integrated neuroendocrine and body-composition-focused disease modification.
EmergingChildhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
A 2026 review found that childhood obesity significantly increases cardiovascular risks, and demonstrated that emerging therapies like retatrutide and oral GLP-1 agents are currently under clinical evaluation to improve weight management adherence.
EmergingNew Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
Structured, mechanism-based nutritional counseling may mitigate gastrointestinal adverse events and improve adherence in patients using incretin-based anti-obesity medications, a 2026 review found. The researchers provided a pragmatic framework combining pharmacology with clinical nutrition to optimize tolerability and patient outcomes.
EmergingMitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
A 2026 in vitro study found that tirzepatide promoted sustained improvements in skeletal muscle mitochondrial respiration under both healthy and lipotoxic conditions. In contrast, semaglutide and cagrilintide demonstrated transient reductions in mitochondrial function that resolved after five days.
PreclinicalEfficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
A 2026 meta-analysis demonstrated that Cagrisema produced significantly greater weight loss than semaglutide, while cagrilintide monotherapy yielded comparable results. The study found the combination therapy offered superior efficacy with a similar overall safety profile, despite slightly higher rates of nausea.
Very StrongCagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
A 2026 meta-analysis found that CagriSema demonstrated superior reductions in body weight, waist circumference, and systolic blood pressure compared to semaglutide monotherapy or placebo. However, the dual therapy was also associated with a higher frequency of gastrointestinal adverse events.
Very Strong§ Safety Profile
Generally well-tolerated in Phase 2 trials. Main side effects are GI-related (nausea, vomiting). Novo Nordisk is developing CagriSema (cagrilintide + semaglutide) as next-gen obesity treatment. Research-only peptide.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
* Dosing data from published literature — not a human use recommendation.
RouteSubQ
Dose Range500–4500 mcg
FrequencyWeekly
TimingAny time, consistent day
Cycle Length12–24 weeks
Clinical trial doses: 0.3-4.5mg weekly with dose escalation over 4-8 weeks. Start low (0.3-0.6mg) and increase every 4 weeks to minimize GI side effects.
§ Pharmacokinetics
⏱️ Half-Life: 7d
Plasma concentration over time§ Expected Outcomes
Week 1
Appetite suppression begins; reduced food cravings
Weeks 2–4
Measurable weight loss (1-2 lbs/week); improved meal portion control
Month 2–3
10-11% body weight loss at clinical doses; improved glycemic markers
Long-term
Clinical trials show sustained weight loss through 26+ weeks; CagriSema in Phase 3 trials
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea Most common during dose escalation; typically resolves in 2-4 weeks | ~25% of users | moderate |
Diarrhea | ~10% of users | mild |
Vomiting | ~8% of users | moderate |
Injection site reaction | ~5% of users | mild |
Constipation | ~8% of users | mild |
Where to Source Cagrilintide for Research
Finding verified, high-purity Cagrilintide requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Cagrilintide✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
PEPTIDEX coupon for CagrilintideSave 20% on Cagrilintide at Amino Club & verified vendors →
Reconstitution CalculatorCalculate reconstitution for Cagrilintide →
Compare ToolCompare Cagrilintide to similar peptides →
Cagrilintide is the amylin analog half of Novo Nordisk's CagriSema combination — paired with semaglutide for what's shaping up to be the most potent obesity pharmacotherapy combination in development. The Phase 3 REDEFINE program data is expected in 2026.
Amino Club batch CAG0001 verified at 99.604% purity via Biogenica Labs. At $55.99/10mg after the PEPTIDEX code, the COA PDF is linked below for independent verification.
The amylin receptor agonism provides a distinct mechanism from GLP-1: amylin slows gastric emptying and reduces glucagon secretion through different receptor pathways. The combination with semaglutide is mechanistically rational because the two receptors don't overlap — it's additive, not redundant.
📄 View COA: CAG0001 (99.604% HPLC, 3951.5 Da)Full disclosure — PEPTIDEX is my affiliate code. Cagrilintide is available from both Amino Club ($5.60/mg) and Ascension Peptides.
Cite This Page
⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer
Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy
Free Download
2026 Peptide Stack Cheat Sheet
12stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author Verified
PeptiDex Research
Independent researcher, not a medical professional
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...
View profileLast fact-checked: · PeptiDex Editorial Team